Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Nexletol

(Bempedoic Acid 180 MG Oral Tablet)

EEsperion Therapeutics, Inc.

0

Indications

1

Total Trials

1

Active Trials

0

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Timeline

Expected Milestones

Q1 2030

Phase 2Not yet recruiting

ADPKD (autosomal Dominant Polycystic Kidney Disease)

NCT07282821

Clinical

Trials by Indication[1]

ADPKD (Autosomal Dominant Polycystic Kidney Disease)1 trial

Bempedoic Acid Therapy for Polycystic Kidney Disease (BEAT-PKD) Randomized Clinical Trial

Not yet recruiting·KKenneth Hallows·Phase 2·NCT07282821·120 enrolled

Regulatory

FDA Approval Timeline[3]

Feb 21, 2020

NEXLETOL

NDA NDA211616

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bempedoic Acid 180 MG Oral Tablet. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bempedoic Acid 180 MG Oral Tablet compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (NDA NDA211616). U.S. Food & Drug Administration.
[4]
SEC EDGAR — Esperion Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Company: EEsperion Therapeutics, Inc.

Related News